share_log

中信建投:持续看好创新药行业

中信建投:持續看好創新藥行業

Breakings ·  Mar 28 00:08

中信建投研報稱,在政策上,集採與醫保談判常態化,商保帶來潛在增量,對創新藥的支持力度有望進一步增加。在技術上,全球ADC藥物2023年銷售額達104億美元,中國相關公司加速ADC佈局與推進,逐漸迎來收穫期;GLP-1減重賽道發展成熟,競爭從單一減重升級到多重獲益,新靶點存在潛在出海機會;IO多抗賽道AK112率先實現突破,TCE技術從血液瘤走向實體瘤和自免。

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Comment Comment · Views 405

Recommended

Write a comment

Statement

This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.